Lumigan and Tabrecta drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among 5 people who take Lumigan and Tabrecta. Common interactions include fatigue among females.

The phase IV clinical study analyzes what interactions people who take Lumigan and Tabrecta have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Oct, 03, 2023

5 people who take Lumigan and Tabrecta together, and have interactions are studied.

What is Lumigan?

Lumigan has active ingredients of bimatoprost. It is used in glaucoma. Currently, eHealthMe is studying from 19,935 Lumigan users.

What is Tabrecta?

Tabrecta has active ingredients of capmatinib hydrochloride. Currently, eHealthMe is studying from 1,782 Tabrecta users.

Number of Lumigan and Tabrecta reports submitted per year:

Common Lumigan and Tabrecta drug interactions by gender *:

female:

Fatigue
Decreased appetite
Dehydration
Feeding disorder
Nausea
Drug ineffective
Blood creatinine increased
Malaise

male:

n/a

Common Lumigan and Tabrecta drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Fatigue
Decreased appetite
Dehydration
Feeding disorder
Nausea
Drug ineffective

* Approximation only. Some reports may have incomplete information.

Do you take Lumigan and Tabrecta?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drug side effects by duration, gender and age:

Lumigan side effects (19,935 reports)
Tabrecta side effects (1,782 reports)

Common Lumigan drug interactions:

Lumigan and Latanoprost: 2,218 reports
Lumigan and Aspirin: 1,882 reports
Lumigan and Combigan: 1,584 reports
Lumigan and Alphagan: 1,525 reports
Lumigan and Azopt: 1,376 reports
Lumigan and Timolol: 1,348 reports
Lumigan and Alphagan p: 1,116 reports
Lumigan and Brimonidine: 1,061 reports
Lumigan and Lisinopril: 1,037 reports
Lumigan and Vitamin d: 963 reports

Browse interactions between Lumigan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse interactions between Tabrecta and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on bimatoprost and capmatinib hydrochloride (the active ingredients of Lumigan and Tabrecta, respectively), and Lumigan and Tabrecta (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Lumigan and Tabrecta.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

Lotronex and Ativan drug interaction - 3 seconds ago
Camptosar and Paraplatin drug interaction - 11 seconds ago
L-Methylfolate and Eliquis drug interaction - 12 seconds ago
Stalevo 100 and Stress And Anxiety - 17 seconds ago
Relpax and Tinnitus - 22 seconds ago
Omeprazole and Renal Cyst - 42 seconds ago
Promacta and Voriconazole drug interaction - 45 seconds ago
Pepcid Rpd and Ultiva drug interaction - 46 seconds ago
Meropenem and Sennosides drug interaction - a minute ago
Tracleer and Urine Odor Abnormal - a minute ago